Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Peristaltic Pump

April 27, 2011 7:55 am | Drug Discovery & Development | Product Releases | Comments

With no seals or valves, Watson-Marlow peristaltic pumps offer contamination-free pumping and are easy to use. The peristaltic pumps are available with custom configurations for fast delivery and lean manufacturing for applications including irrigation, washing and cooling, vacuum and aspiration, and reagent dilution and sampling.


Zyleris Launches Drug Development Service

April 27, 2011 7:40 am | News | Comments

Zyleris PharmaTech has announced the launch of a new drug development service: high-throughput screening of compound library to identify drug candidates for topical and transdermal delivery.


Nabi Hits Final Milestone in GSK Staph Deal

April 27, 2011 7:36 am | News | Comments

Nabi Biopharmaceuticals has completed the Phase 1 trial for two of the PentaStaph antigens. Completion of this trial was the final milestone associated with the sale of the PentaStaph vaccine to GlaxoSmithKline.


Protein Inhibitor May Topically Treat HPV

April 27, 2011 7:30 am | News | Comments

Thanks to new research, patients infected with cancer-causing HPV may someday have an alternative to surgical and harsh chemical treatments. Scientists report on the development of a protein-based inhibitor that could provide a topical treatment for HPV.


Expert Helps Pinpoint Best Treatment for GTN

April 27, 2011 7:28 am | News | Comments

A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.


Enrollment Wraps Up in Phase 3 Pain Trial

April 27, 2011 7:20 am | News | Comments

QRxPharma Limited announced it has completed patient enrolment for Study 022, a Phase 3 trial comparing the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone alone.


FDA: Hepatitis Drug Is Highly Effective

April 27, 2011 7:18 am | by Matthew Perrone | News | Comments

Federal health officials said a highly anticipated hepatitis C drug from Vertex Pharmaceuticals successfully treats the majority of patients with the virus in less time than older medicines that have been used for 20 years.


Push for More Drugs for Deadly, Rare Diseases

April 27, 2011 7:16 am | by Lauran Neergaard | News | Comments

Every other week, 7-year-old twins Addison and Cassidy Hempel have an experimental medicine injected into their spines in hopes of battling a rare, fatal disease. And it's their mom who made that possible.


Hospira Income Up 6% in First Quarter

April 27, 2011 7:12 am | News | Comments

Drug and medical device maker Hospira Inc. said its net income rose 6 percent in the first quarter on strong sales of new products, including generic versions of the cancer drugs Gemzar and Taxotere.


Medtronic, Eli Lilly Collaborate on Parkinson's

April 27, 2011 7:09 am | News | Comments

Medical device maker Medtronic and drugmaker Eli Lilly said they will collaborate on an implantable drug delivery system to treat Parkinson's disease, the debilitating brain disorder that causes tremors and movement problems.


What to Expect from BMS

April 27, 2011 7:08 am | News | Comments

Drugmaker Bristol-Myers Squibb Co., which recently got approval of an important new skin cancer drug but is facing a sharp revenue drop next year, will report first-quarter results before the stock market opens Thursday.


Regeneron Cancer Drug Meets Study Goals

April 27, 2011 7:05 am | News | Comments

Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis' potential cancer drug met key goals in a late-stage study focusing on colon cancer patients.


Merck Approves $5B in Stock Buybacks

April 27, 2011 7:02 am | News | Comments

Merck & Co. Inc. said its board of directors approved the buyback of up to $5 billion in common stock for the drug developer's treasury. Overall, the company is now authorized to buy back up to $6.4 billion in common stock.


J & J Buying Synthes for $21.3B

April 27, 2011 6:59 am | by Frank Jordans | News | Comments

Health products giant Johnson & Johnson said it will buy U.S.-Swiss medical device maker Synthes Inc. for $21.3 billion, greatly increasing its share of the market for surgical trauma equipment and orthopedic implants.


API Toolkit

April 26, 2011 8:31 am | Product Releases | Comments

Sage-N Research, Inc. announced a new API toolkit for developers of proteomics data analysis software. The toolkit will enable software developers to add the power and sensitivity of SORCERER analyses to their existing software packages.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.